Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile

References

• Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219–31
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97:28–38
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet 2007;370:685–97
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74
   PubMed Web of Science ®Google Scholar
• Cankaya S, Demir B, Aksakal SE, et al. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. Fertil Steril 2014;102:826–30
   PubMed Web of Science ®Google Scholar
• Trebotic LK, Klimek P, Thomas A, et al. Circulating betatrophin is strongly increased in pregnancy and gestational diabetes mellitus. PLoS One 2015;10:e0136701
   PubMed Web of Science ®Google Scholar
• Yamada H, Saito T, Aoki A, et al. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J 2015;62:417–21
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Pascual E, Catalán V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014;99:E2004–9
   PubMed Web of Science ®Google Scholar
• Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 2014;57:1204–8
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, et al. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012;16:1203–14
   PubMed Web of Science ®Google Scholar
• Murahovschi V, Pivovarova O, Ilkavets I, et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 2015;64:856–66
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62
   PubMed Web of Science ®Google Scholar
• La Marca A, Malmusi S, Giulini S, et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004;19:2738–41
   PubMed Web of Science ®Google Scholar
• Nardo LG, Yates AP, Roberts SA, et al. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009;24:2917–23
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495–9
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Hayashi N, Akamatsu H, Kawashima M. Establishment of grading criteria for acne severity. J Dermatol 2008;35:255–60
   PubMed Web of Science ®Google Scholar
• Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97:247–54
   PubMed Web of Science ®Google Scholar
• Maiese K. Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regen Res 2015;10:518–28
   PubMed Web of Science ®Google Scholar
• Palsgaard J, Emanuelli B, Winnay JN, et al. Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J Biol Chem 2012;287:12016–26
   PubMed Web of Science ®Google Scholar
• Gennarelli G, Holte J, Berglund L, et al. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod 2000;15:2098–102
   PubMed Web of Science ®Google Scholar
• Berwick DC, Harvey K. The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol 2014;6:3–12
   PubMed Web of Science ®Google Scholar
• Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429–33
   PubMed Web of Science ®Google Scholar
• Masuda M, Sawa M, Yamada T. Therapeutic targets in the Wnt signaling pathway: feasibility of targeting TNIK in colorectal cancer. Pharmacol Ther 2015;156:1–9
   PubMed Web of Science ®Google Scholar
• Erbag G, Eroglu M, Turkon H, et al. Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome. Cell Mol Biol (Noisy-le-Grand) 2016;62:20–4
   PubMed Web of Science ®Google Scholar
• Calan M, Yilmaz O, Kume T, et al. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine 2016;53:271–9
   PubMed Web of Science ®Google Scholar
• Sahin Ersoy G, Altun Ensari T, Subas S, et al. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Fetal Neonatal Med 2016;1–5. [Epub ahead of print]
   PubMedGoogle Scholar
• Gusarova V, Alexa CA, Na E, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 2014;159:691–6
   PubMed Web of Science ®Google Scholar
• Wild R, Carmina E. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: consensus statement by the androgen excess and poly cystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab 2010;95:2038–49
   PubMed Web of Science ®Google Scholar